The FDA has approved the steroid prasterone (Intrarosa – Endoceutics) for intravaginal treatment of postmenopausal women with moderate-to-severe dyspareunia due to vulvovaginal atrophy (VVA) (Table 1). Also called dehydroepiandrosterone (DHEA), prasterone is produced in the adrenal glands, gonads, and brain and converted intracellularly into active metabolites of estrogens and androgens. DHEA has been available over the counter for years as an oral dietary supplement claimed to benefit sexual, cardiovascular, and neuropsychiatric dysfunction.1-3
Prasterone (Intrarosa) for Dyspareunia. JAMA. 2017;318(16):1607–1608. doi:10.1001/jama.2017.14981
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: